logo
Plus   Neg
Share
Email

Vanda Pharmaceuticals (VNDA) Has Spiked To A New High On Study Results

Vanda Pharmaceuticals (VNDA) announced Monday morning that its Phase 2 study of tradipitant, in patients with idiopathic and diabetic gastroparesis, met the primary endpoint.

Vanda Pharmaceuticals gapped up at the open Monday and has risen sharply in early trade. Shares are now up 3.87 at $28.91. The stock has surged to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Momentum

0 Articles
Follow RTT